Photo of Ashley Woozley

Effective October 1, 2025, Maryland House Bill 895, titled the Employment and Insurance Equality for Service Members Act broadens the definition of “Uniformed Services” to include not only the Armed Forces, but also the Commissioned Corps of the Public Health Service and the National Oceanic and Atmospheric Administration (“NOAA”).  This expansion has two key implications

  • Employers preparing for the January 1, 2026, rollout of Delaware’s Paid Family Medical Leave Insurance Program should review recent amendments to the Healthy Delaware Families Act. Among other things, the amendments prohibit employers from requiring employees to use employer-provided paid time off such as vacation or sick leave before using Paid Family Leave

The Maryland Department of Labor is proposing delaying implementation of the Family and Medical Leave Insurance (FAMLI) program. Under the new recommended plan, payroll deductions would begin January 1, 2027 and benefits would become available on January 1, 2028. This proposed change will need to be approved by the General Assembly. In light of the

As more employers incorporate wearable technology in the workplace, including those enhanced by artificial intelligence, the Equal Employment Opportunity Commission (EEOC)’s new fact sheet “Wearables in the Workplace: The Use of Wearables and Other Monitoring Technology Under Federal Employment Discrimination Laws,” offers important considerations for employers.  The EEOC explains how employers can navigate

The Maryland Department of Labor recently published proposed regulations to implement the state’s paid family and medical leave insurance program. Although they are not final yet, the proposed regulations provide important information for employers as they prepare for the new mandatory program. Payroll deductions will start July 1, 2025, and benefits will be available beginning

The DOL Wage and Hour Division’s recently issued opinion letter clarifies the scope of permitted uses of Family Medical Leave Act leave. Specifically, it affirms that eligible employees may use FMLA leave for medical interventions provided as part of clinical trials, regardless of whether the treatment is experimental or involves placebos. Highlights from the DOL’s